AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 265.01 |
Market Cap | 143.52B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 7.84 |
PE Ratio (ttm) | 34.06 |
Forward PE | n/a |
Analyst | Hold |
Ask | 267.99 |
Volume | 1,996,433 |
Avg. Volume (20D) | 3,444,575 |
Open | 271.61 |
Previous Close | 270.19 |
Day's Range | 264.91 - 271.61 |
52-Week Range | 253.30 - 346.85 |
Beta | undefined |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopaus...
Analyst Forecast
According to 23 analyst ratings, the average rating for AMGN stock is "Hold." The 12-month stock price forecast is $328, which is an increase of 22.85% from the latest price.
Next Earnings Release
Analysts project revenue of $8.85B, reflecting a 7.98% YoY growth and earnings per share of 5.03, making a 6.79% increase YoY.